Product Pipeline

We have several ZFP Therapeutic® programs under development. By functioning at the DNA level our technology enables us to achieve unique biologic outcomes in the treatment of unmet medical needs.

We are using engineered zinc finger DNA-binding protein transcription factors (ZFP TFs) to "up-regulate"  or "down-regulate" gene expression to achieve a desired therapeutic effect. We are also using zinc finger nucleases (ZFNs) to correct or disrupt genes to address diseases caused by a defect in a single gene, so called “monogenic diseases”.

We are currently developing the following ZFP Therapeutics (Note:  In October 2011, we announced that we will complete follow up on the SB-509 Phase 2b trial but discontinue any further development of the drug.)